Floatz logo

AN ADENOVIRUS VECTOR CANCER VACCINE COMPOSED OF A REPLICATION-DEFECTIVE, SER OTYPE 5 ADENOVIRUS (AD5) THAT HAS BEEN MODIFIED BY REMOVAL OF THE E1, E2B AND E3 GENES AND INSERTION OF A MODIFIED HUMAN MUCIN 1 GENE ENCODING AGONIST EPITOPES DESIGNED TO INCREASE CYTOTOXIC T LYMPHOCYTE ANTITUMOR IMMUNE RESPONSES

Lung Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
D
29/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
17/ 100
Competitive Position
65/ 100

Competitive context

304 Active assets in the Lung Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
SystImmune Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
University of Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

AN ADENOVIRUS VECTOR CANCER VACCINE COMPOSED OF A REPLICATION-DEFECTIVE, SER OTYPE 5 ADENOVIRUS (AD5) THAT HAS BEEN MODIFIED BY REMOVAL OF THE E1, E2B AND E3 GENES AND INSERTION OF A MODIFIED HUMAN MUCIN 1 GENE ENCODING AGONIST EPITOPES DESIGNED TO INCREASE CYTOTOXIC T LYMPHOCYTE ANTITUMOR IMMUNE RESPONSES is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
40 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →